Tipifarnib

Pre-clinicalActive

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Conditions

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Trial Timeline

— → —

NCT ID

NCT04809233

About Tipifarnib

Tipifarnib is a pre-clinical stage product being developed by Kura Oncology for HRAS Mutations or Peripheral T Cell Lymphoma (PTCL). The current trial status is active. This product is registered under clinical trial identifier NCT04809233. Target conditions include HRAS Mutations or Peripheral T Cell Lymphoma (PTCL).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04809233	Pre-clinical	Active	—	—	HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
NCT04865159	Phase 1	Terminated	May 6, 2021	May 2, 2023	Advanced Solid Tumor
NCT03719690	Phase 2	Completed	Mar 15, 2019	May 2, 2023	HRAS Gene Mutation
NCT02807272	Phase 2	Completed	Jan 10, 2017	Nov 30, 2020	Leukemia, Myelomonocytic, Chronic
NCT02779777	Phase 2	Terminated	Jun 1, 2016	Aug 28, 2018	Myelodysplastic Syndromes
NCT02464228	Phase 2	Completed	Feb 25, 2016	Mar 31, 2021	Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT02383927	Phase 2	Completed	May 13, 2015	Dec 14, 2020	Thyroid Cancer

Competing Products

2 competing products in HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

See all competitors

Product	Company	Stage	Hype Score
Darlifarnib + Cabozantinib + Adagrasib	Kura Oncology	Phase 1	30
Tipifarnib	Kura Oncology	Phase 2	29